Trials / Completed
CompletedNCT02190149
Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- 13 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ADVATE (Antihemophilic Factor [Recombinant]) | |
| BIOLOGICAL | RIXUBIS (Coagulation Factor IX [Recombinant]) |
Timeline
- Start date
- 2014-07-22
- Primary completion
- 2016-03-29
- Completion
- 2016-03-29
- First posted
- 2014-07-15
- Last updated
- 2021-03-17
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02190149. Inclusion in this directory is not an endorsement.